Table 4 Anticoagulated-related hematoma: reversal management
From: Ilio-psoas hematoma in the intensive care unit: a multicentric study
Anticoagulated-related hematoma | All | Died | Alive | p value |
|---|---|---|---|---|
VKA-related hematoma, n | 21 | 5 | 16 | |
Reversal management | ||||
No reversal, n (%) | 8 (38) | 1 (20) | 7 (44) | ns |
No guideline-concordant reversal, n (%) | 6 (29) | 2 (40) | 4 (25) | ns |
Guideline-concordant reversal, n (%) | 7 (33) | 2 (40) | 5 (31) | ns |
INR at diagnosis | ||||
Normal (INR < 1.5), n (%) | 0 (0) | 0 (0) | 0 (0) | ns |
Therapeutic (INR between 1.5 and 4), n (%) | 8 (38) | 3 (50) | 5 (33) | ns |
Supratherapeutic (INR > 4), n (%) | 9 (57) | 1 (17) | 8 (53) | ns |
Missing values, n (%) | 4 (19) | 2 (33) | 2 (13) | ns |
Unfractionned heparin-related hematoma, n | 23 | 6 | 17 | |
Protamine reversal, n (%) | 3 (13) | 1 (17) | 2 (12) | ns |
Low molecular weight heparin-related hematoma, n | 12 | 3 | 9 | |
Protamine reversal, n (%) | 1 (8) | 0 (0) | 1 (11) | ns |